DNA Ginkgo Bioworks Holdings, Inc.
Healthcare$8.69+3.33%ClosedMarket Cap: $567.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.13
P/S
3.89
EV/EBITDA
-3.96
DCF Value
$-32.64
FCF Yield
-33.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.0%
Operating Margin
-210.7%
Net Margin
-215.4%
ROE
-57.3%
ROA
-29.5%
ROIC
-31.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $19.5M | 18.4% | $-71.4M | $-82.6M | $— | — |
| Q4 null | $33.4M | 124.4% | $-70.8M | $-80.8M | $— | — |
| FY null | $170.2M | 81.5% | $-315.3M | $-312.8M | $— | — |
| Q3 null | $38.8M | 67.0% | $-90.0M | $-80.8M | $— | — |
| Q2 null | $49.6M | 70.1% | $-65.5M | $-60.3M | $— | — |
| Q1 null | $48.3M | 75.1% | $-89.0M | $-91.0M | $— | — |
| Q4 null | $43.8M | 78.1% | $-103.6M | $-107.5M | $— | — |
| FY null | $227.0M | 83.0% | $-559.8M | $-547.0M | $— | — |
| Q3 null | $89.0M | 88.8% | $-55.2M | $-56.4M | $— | — |
| Q2 null | $56.2M | 75.6% | $-222.9M | $-217.2M | $— | — |
| Q1 null | $37.9M | 75.7% | $-178.0M | $-165.9M | $— | — |
| Q4 2023 | $34.8M | 81.0% | $-178.1M | $-211.7M | $-4.31 | — |